Cleave Biosciences Receives $37,000,000 Series B Financing

  • Feed Type
  • Date
    8/9/2016
  • Company Name
    Cleave Biosciences
  • Mailing Address
    866 Malcolm Burlingame, CA 94010 USA
  • Company Description
    Cleave Biosciences is focused on targets in cellular protein homeostasis pathways controlled by the ubiquitin proteasome and the autophagy systems, which are utilized by cancer cells in their growth and survival.
  • Website
    http://www.cleavebio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $37,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The funds will be used to support further clinical development of CB-5083, the company’s lead oncology drug candidate, and discovery efforts related to the company’s AAA ATPase platform.
  • M&A Terms
  • Venture Investor
    Celgene
  • Venture Investor
    Nextech Invest
  • Venture Investor
    Arcus Ventures
  • Venture Investor
    5AM Ventures
  • Venture Investor
    Clarus Ventures
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    OrbiMed
  • Venture Investor
    U.S. Venture Partners
  • Venture Investor
    Astellas Venture Capital
  • Venture Investor
    Osage Partners

Trending on Xconomy